336 related articles for article (PubMed ID: 28837372)
1. Update upon efficacy and safety of etanercept for the treatment of spondyloarthritis and juvenile idiopathic arthritis.
Murdaca G; Negrini S; Magnani O; Penza E; Pellecchio M; Gulli R; Mandich P; Puppo F
Mod Rheumatol; 2018 May; 28(3):417-431. PubMed ID: 28837372
[TBL] [Abstract][Full Text] [Related]
2. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
3. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Klotsche J; Niewerth M; Haas JP; Huppertz HI; Zink A; Horneff G; Minden K
Ann Rheum Dis; 2016 May; 75(5):855-61. PubMed ID: 25926155
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
8. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
[TBL] [Abstract][Full Text] [Related]
9. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
[TBL] [Abstract][Full Text] [Related]
10. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
[TBL] [Abstract][Full Text] [Related]
11. Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting.
Pastore S; Naviglio S; Canuto A; Lepore L; Martelossi S; Ventura A; Taddio A
Paediatr Drugs; 2018 Apr; 20(2):165-171. PubMed ID: 29214394
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
[TBL] [Abstract][Full Text] [Related]
13. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
14. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of etanercept in chronic immune-mediated disease.
Murdaca G; Spanò F; Contatore M; Guastalla A; Magnani O; Puppo F
Expert Opin Drug Saf; 2014 May; 13(5):649-61. PubMed ID: 24654562
[TBL] [Abstract][Full Text] [Related]
16. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
[TBL] [Abstract][Full Text] [Related]
17. Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants.
Eworuke E; Panucci G; Goulding M; Neuner R; Toh S
Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):296-304. PubMed ID: 30430682
[TBL] [Abstract][Full Text] [Related]
18. The clinical application of etanercept in Chinese patients with rheumatic diseases.
Chou CT
Mod Rheumatol; 2006; 16(4):206-13. PubMed ID: 16906369
[TBL] [Abstract][Full Text] [Related]
19. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]